Dr. Thomas Marron explains how therapeutic vaccines differ from preventative vaccines in lung cancer care.
Dr. Thomas Marron
Advertisement
Dr. Thomas Marron, a medical oncologist whose research focuses on the development of cancer immunotherapies, is the director of the Early Phase Trials Unit at The Tisch Cancer Institute, Professor of Medicine (Hematology and Medical Oncology), and Professor of Immunology and Immunotherapy at the Icahn School of Medicine at Mount Sinai in New York.
Articles by Dr. Thomas Marron
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma
2
11 Years Living With Stage 4 Cancer Inspires Gratitude and Reflection
3
Every FDA Oncology Approval From November 2025
4
What Patients Should Know About EGFR Mutated Lung Cancer Treatment
5
